|Bid||0.0000 x 1800|
|Ask||0.0000 x 800|
|Day's Range||3.4400 - 3.5899|
|52 Week Range||3.2000 - 14.5400|
|Beta (3Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 15, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.42|
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Control4 Corp (NASDAQ:CTRL) based on that data. […]
Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.
As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long...
Alpine gets $2 million from Adaptimmune now, and up to $290 million if the partnership is successful in producing next-generation cancer immunotherapies.
Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced a collaboration and license agreement to develop next-generation SPEAR T-cell products which incorporate Alpine’s secreted and transmembrane immunomodulatory protein (termed SIP™ and TIP™) technology. This collaboration will further enhance Adaptimmune’s efforts to design and develop next-generation SPEAR T-cell therapies. “SPEAR T-cell therapies have demonstrated clinical promise for the treatment of solid tumors.
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom, May 06, 2019 -- Adaptimmune.
- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4.
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical.
- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells.
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.
PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety.
PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising.
If you're interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
- On track for clinical data update from trials in multiple solid tumors at the Q1 2019 earnings update call in May - - Completed initial safety cohorts for ADP-A2M10.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! James Noble became the CEO of AdaptimmuneRead More...
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the.